Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Digestive Diseases and Sciences
|
May 14, 2011
Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease
Antonio Tursi, Raymond E Joseph, Paul Streck
Gastroenterology
|
March 3, 2015
Reply: To PMID 25167986
Jeffrey B Raskin, Michael A Kamm, Paul Streck
The American Journal of Gastroenterology
|
May 9, 2012
Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis
Geert D'Haens, William J Sandborn, Karen Barrett, et al.
European Journal of Clinical Pharmacology
|
March 11, 2014
Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine
Leo Russo, Gary Schneider, Margarita Hauser Gardiner, et al.
Gastroenterology
|
July 20, 2014
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials
Jeffrey B Raskin, Michael A Kamm, M Mazen Jamal, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Digestive Diseases and Sciences
|
May 14, 2011
Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease
Antonio Tursi, Raymond E Joseph, Paul Streck
Gastroenterology
|
March 3, 2015
Reply: To PMID 25167986
Jeffrey B Raskin, Michael A Kamm, Paul Streck
The American Journal of Gastroenterology
|
May 9, 2012
Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis
Geert D'Haens, William J Sandborn, Karen Barrett, et al.
European Journal of Clinical Pharmacology
|
March 11, 2014
Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine
Leo Russo, Gary Schneider, Margarita Hauser Gardiner, et al.
Gastroenterology
|
July 20, 2014
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials
Jeffrey B Raskin, Michael A Kamm, M Mazen Jamal, et al.
Page
of 1